{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T01:39:39Z","timestamp":1773279579188,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,10,21]],"date-time":"2008-10-21T00:00:00Z","timestamp":1224547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmied Arch Pharmacol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00210-008-0363-y","type":"journal-article","created":{"date-parts":[[2008,10,20]],"date-time":"2008-10-20T08:00:16Z","timestamp":1224489616000},"page":"241-251","source":"Crossref","is-referenced-by-count":20,"title":["A role for atorvastatin and insulin combination in protecting from liver injury in a model of type 2 diabetes with hyperlipidemia"],"prefix":"10.1007","volume":"379","author":[{"given":"P.","family":"Matafome","sequence":"first","affiliation":[]},{"given":"E.","family":"Nunes","sequence":"additional","affiliation":[]},{"given":"T.","family":"Louro","sequence":"additional","affiliation":[]},{"given":"C.","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"J.","family":"Cris\u00f3stomo","sequence":"additional","affiliation":[]},{"given":"L.","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"A. R.","family":"Moedas","sequence":"additional","affiliation":[]},{"given":"P.","family":"Monteiro","sequence":"additional","affiliation":[]},{"given":"A.","family":"Cipriano","sequence":"additional","affiliation":[]},{"given":"R.","family":"Sei\u00e7a","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2008,10,21]]},"reference":[{"key":"363_CR1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00125-006-0205-8","volume":"49","author":"A Aas","year":"2006","unstructured":"Aas A, Seljeflot I, Torjesen P, Diep L, Thorsby P, Birkeland K (2006) Blood glucose lowering by lifestyle intervention has different effects on adipokines as compared with insulin treatment in subjects with type 2 diabetes. Diabetologia 49:872\u2013880","journal-title":"Diabetologia"},{"key":"363_CR2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1185\/030079906X104696","volume":"22","author":"V Athyros","year":"2006","unstructured":"Athyros V, Mikhailidis D, Didangelos T, Giouleme O, Liberopoulos E, Karagiannis A et al (2006) Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 22:873\u2013883","journal-title":"Curr Med Res Opin"},{"key":"363_CR3","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1016\/j.transproceed.2005.08.064","volume":"37","author":"B Bay\u00e9s","year":"2005","unstructured":"Bay\u00e9s B, Granada ML, Lauzurica R, Pastor MC, Navarro M, Bonet J, Llopis MA, Romero R (2005) Effect of low doses of atorvastatin on adiponectin, glucose homeostasis, and clinical inflammatory markers in kidney transplant recipients. Transplant Proc 37:3808\u20133812","journal-title":"Transplant Proc"},{"key":"363_CR4","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0022-2275(20)30035-3","volume":"38","author":"C Bisgaier","year":"1997","unstructured":"Bisgaier C, Essenburg A, Auerbach B, Pape M, Sekerke C, Gee A, W\u00f6lle S, Newton R (1997) Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors. J Lipid Res 38:2502\u20132525","journal-title":"J Lipid Res"},{"key":"363_CR5","doi-asserted-by":"crossref","first-page":"G194","DOI":"10.1152\/ajpgi.00413.2005","volume":"290","author":"M Bradbury","year":"2006","unstructured":"Bradbury M (2006) Lipid metabolism and liver inflammation. Am J Physiol Gastrointest Liver Physiol 290:G194\u2013G198","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"363_CR6","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","volume":"54","author":"M Brownlee","year":"2005","unstructured":"Brownlee M (2005) The pathobiology of diabetic complications. Diabetes 54:1615\u201325","journal-title":"Diabetes"},{"key":"363_CR7","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","volume":"48","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, Gastaldelli A, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M (2005a) Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48:634\u2013642","journal-title":"Diabetologia"},{"key":"363_CR8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/hep.20920","volume":"42","author":"E Bugianesi","year":"2005","unstructured":"Bugianesi E, McCullough A, Marchesini G (2005b) Insulin resistance. Hepatology 42:987\u20131000","journal-title":"Hepatology"},{"key":"363_CR9","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jnutbio.2006.12.006","volume":"18","author":"M Cave","year":"2007","unstructured":"Cave M, Deaciuc I, Mendez C, Song Z, Joshi-Barve S, Barve S, McClain C (2007) Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. J Nutr Biochem 18:184\u2013195","journal-title":"J Nutr Biochem"},{"key":"363_CR10","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.2337\/diabetes.54.7.1914","volume":"54","author":"H Chen","year":"2005","unstructured":"Chen H, Sullivan G, Quon MJ (2005) Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 54:1914\u20131925","journal-title":"Diabetes"},{"key":"363_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijcard.2006.11.010","volume":"122","author":"C Chrysohoou","year":"2006","unstructured":"Chrysohoou C, Pitsavos C, Skoumas J, Masoura C (2006) The emerging anti-inflammatory role of HDL-cholesterol, illustrated in cardiovascular disease free population, the ATTICA Study. Int J Cardiol 122:29\u201333","journal-title":"Int J Cardiol"},{"key":"363_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2036.2006.02751.x","volume":"23","author":"K Comar","year":"2006","unstructured":"Comar K, Sterling R (2006) Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 23:207\u2013215","journal-title":"Aliment Pharmacol Ther"},{"key":"363_CR13","doi-asserted-by":"crossref","first-page":"3K","DOI":"10.1016\/j.amjcard.2005.08.002","volume":"96","author":"M Davidson","year":"2005","unstructured":"Davidson M (2005) Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 96:3K\u201313K","journal-title":"Am J Cardiol"},{"key":"363_CR14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jhep.2007.02.013","volume":"47","author":"M Ekstedt","year":"2007","unstructured":"Ekstedt M, Franz\u00e9n L, Mathiesen U, Holmqvist M, Bodemar G, Kechagias S (2007) Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study. J Hepatol 47:135\u2013141","journal-title":"J Hepatol"},{"key":"363_CR15","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.dld.2006.04.009","volume":"38","author":"A Federico","year":"2006","unstructured":"Federico A, Trappoliere C, Loguercio C (2006) Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives. Dig Liver Dis 38:789\u2013801","journal-title":"Dig Liver Dis"},{"key":"363_CR16","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.metabol.2006.11.007","volume":"56","author":"T Forst","year":"2007","unstructured":"Forst T, Pf\u00fctzner A, L\u00fcbben G, Weber M, Marx N, Karagiannis E et al (2007) Effect of simvastatin and\/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and pro-insulin levels in nondiabetic patients at cardiovascular risk\u2014the PIOSTAT Study. Metabolism 56:491\u2013496","journal-title":"Metabolism"},{"key":"363_CR17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1507\/endocrj.52.427","volume":"52","author":"H Fujita","year":"2005","unstructured":"Fujita H, Fujishima H, Koshimura J, Hosoba M, Yoshioka T, Shimotomai T et al (2005) Effects of antidiabetic treatment with metformin and insulin on serum and adipose tissue adiponectin levels in db\/db mice. Endoc J 52:427\u2013433","journal-title":"Endoc J"},{"key":"363_CR18","first-page":"39","volume":"16","author":"E Georgescu","year":"2007","unstructured":"Georgescu E, Georgescu M (2007) Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointest Liver Dis 16:39\u201346","journal-title":"J Gastrointest Liver Dis"},{"key":"363_CR19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1111\/j.1365-2036.2006.02926.x","volume":"23","author":"E G\u00f3mez-Dom\u00ednguez","year":"2006","unstructured":"G\u00f3mez-Dom\u00ednguez E, Gisbert JP, Moreno-Monteagudo JA, Garc\u00eda-Buey L, Moreno-Otero R (2006) A pilot study of atorvastatin treatment in dyslipemic, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 23:1643\u20131647","journal-title":"Aliment Pharmacol Ther"},{"key":"363_CR20","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1074\/mcp.M600120-MCP200","volume":"6","author":"P Grimsrud","year":"2007","unstructured":"Grimsrud P, Picklo M, Griffin T, Bernlohr D (2007) Carbonylation of adipose proteins in obesity and insulin resistance: identification of adipocyte fatty acid-binding protein as a cellular target of 4-hydroxynonenal. Mol Cell Proteomics 6:624\u201337","journal-title":"Mol Cell Proteomics"},{"key":"363_CR21","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.2337\/diabetes.54.11.3140","volume":"54","author":"A Hanley","year":"2005","unstructured":"Hanley A, Williams K, Festa A, Wagenknecht L, D\u2019Agostino R, Haffner S (2005) Liver markers and development of the metabolic syndrome. Diabetes 54:3140\u20133147","journal-title":"Diabetes"},{"key":"363_CR22","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.amjcard.2006.07.047","volume":"98","author":"T Hernandez","year":"2006","unstructured":"Hernandez T, Capell W, Wolfe P, Gerard L, Eckel R (2006) Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus. Am J Cardiol 98:1656\u20131659","journal-title":"Am J Cardiol"},{"key":"363_CR23","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00109-005-0640-x","volume":"83","author":"H Kaneto","year":"2005","unstructured":"Kaneto H, Matsuoka T, Nakatani Y, Kawamori D, Miyatsuka T, Matsuhisa M, Yamasaki Y (2005) Oxidative stress, ER stress and the JNK pathway in type 2 diabetes. J Mol Med 83:429\u2013439","journal-title":"J Mol Med"},{"key":"363_CR24","first-page":"1010","volume":"231","author":"H Lam","year":"2006","unstructured":"Lam H, Chu C, Wei M, Keng H, Lu C, Sun C et al (2006) The effects of different doses of atorvastatin on plasma endothelin-1 levels in type 2 diabetic patients with dyslipidemia. Exp Biol Med 231:1010\u20131015","journal-title":"Exp Biol Med"},{"key":"363_CR25","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.diabres.2005.03.025","volume":"70","author":"S Ludwig","year":"2005","unstructured":"Ludwig S, Dharmalingam S, Erickson-Nesmith S, Ren S, Zhu F, Ma G et al (2005) Impact of simvastatin on homeostatic and fibrinolytic regulators in type 2 diabetes mellitus. Diabetes Res Clin Pract 70:110\u2013118","journal-title":"Diabetes Res Clin Pract"},{"key":"363_CR26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.cmet.2004.12.008","volume":"1","author":"K Maeda","year":"2005","unstructured":"Maeda K, Cao H, Kono K, Gorgun C, Furuhashi M, Uysal K et al (2005) Adipocyte\/macrophage fatty acid binding proteins control integrated metabolic responses in obesity and diabetes. Cell Metab 1:107\u2013119","journal-title":"Cell Metab"},{"key":"363_CR27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/01.mol.0000180166.08196.07","volume":"16","author":"L Makowski","year":"2005","unstructured":"Makowski L, Hotamisligil G (2005) The role of fatty acid binding protein in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 16:543\u2013548","journal-title":"Curr Opin Lipidol"},{"key":"363_CR28","first-page":"713","volume-title":"Ischemic heart disease","author":"A Maseri","year":"1995","unstructured":"Maseri A (1995) In: Maseri A (ed) Ischemic heart disease. Churchill Livingstone, New York, p 713"},{"key":"363_CR29","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2007.02.024","volume":"564","author":"W M\u00e4user","year":"2007","unstructured":"M\u00e4user W, Perwitz N, Meier B, Fasshauer M, Klein J (2007) Direct adipotropic actions of atorvastatin: differentiation state-dependent induction of apoptosis, modulation of endocrine function and inhibition of glucose uptake. Eur J Pharm 564:37\u201346","journal-title":"Eur J Pharm"},{"key":"363_CR30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1373\/clinchem.2004.032482","volume":"50","author":"U Meier","year":"2004","unstructured":"Meier U, Gressner A (2004) Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin and resistin. Clin Chem 50:1511\u20131525","journal-title":"Clin Chem"},{"key":"363_CR31","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/00000441-200512000-00011","volume":"330","author":"B Neuschwander-Tetri","year":"2005","unstructured":"Neuschwander-Tetri B (2005) Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330:326\u2013335","journal-title":"Am J Med Sci"},{"key":"363_CR32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00592-007-0252-8","volume":"44","author":"E Nunes","year":"2007","unstructured":"Nunes E, Peixoto F, Louro T, Sena CM, Santos MS, Matafome P, Moreira PI, Sei\u00e7a R (2007) Soybean oil treatment impairs glucose-stimulated insulin secretion and changes fatty acid composition of normal and diabetic islets. Acta Diabetol 44:121\u2013130","journal-title":"Acta Diabetol"},{"key":"363_CR33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.gastro.2006.10.014","volume":"132","author":"T Ota","year":"2007","unstructured":"Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, Uno M et al (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology 132:282\u2013293","journal-title":"Gastroenterology"},{"key":"363_CR34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/01.RES.0000202706.70992.95","volume":"98","author":"R Paumelle","year":"2006","unstructured":"Paumelle R, Blanquart C, Briand O, Barbier O, Duhem C, Woerly G et al (2006) Acute anti-inflamatory properties of statins involve peroxissome proliferator-activated receptor-\u03b1 via inhibition of the protein kinase C signalling pathway. Circ Res 98:361\u2013369","journal-title":"Circ Res"},{"key":"363_CR35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1089\/dia.2006.8.28","volume":"8","author":"A Pf\u00fctzner","year":"2006","unstructured":"Pf\u00fctzner A, Forst T (2006) High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 8:28\u201336","journal-title":"Diabetes Technol Ther"},{"key":"363_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bbalip.2004.11.004","volume":"1687","author":"A Planavila","year":"2005","unstructured":"Planavila A, Juan L, V\u00e1squez-Carrera M (2005) Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-kappaB activation. Biochim Biophys Acta 1687:76\u201383","journal-title":"Biochim Biophys Acta"},{"key":"363_CR37","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1248\/bpb.28.2092","volume":"28","author":"K Satoh","year":"2005","unstructured":"Satoh K, Keimatsu N, Kanda M, Kasai T, Takaguri A, Sun F, Ichihara K (2005) HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto\u2013Kakizaki rats. Biol Pharm Bull 28:2092\u20132095","journal-title":"Biol Pharm Bull"},{"key":"363_CR38","first-page":"42","volume":"17","author":"RM Sei\u00e7a","year":"2004","unstructured":"Sei\u00e7a RM, Suzuki KI, Santos RM, Ros\u00e1rio LM (2004) Defici\u00eancia prim\u00e1ria da secre\u00e7\u00e3o de insulina de ilh\u00e9us isolados de ratos Goto\u2013Kakizaki, um modelo animal de diabetes tipo 2 n\u00e3o obesa. Acta Med Port 17:42\u201348","journal-title":"Acta Med Port"},{"key":"363_CR39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/scdb.1998.0273","volume":"10","author":"J Sethi","year":"1999","unstructured":"Sethi J, Hotamisligil G (1999) The role of TNF\u03b1 in adipocyte metabolism. Sem Cell Dev Biol 10:19\u201329","journal-title":"Sem Cell Dev Biol"},{"key":"363_CR40","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/00006676-200211000-00012","volume":"25","author":"W Shang","year":"2002","unstructured":"Shang W, Yasuda K, Takahashi A, Hamasaki A, Takehiro M, Nabe K et al (2002) Effect of high dietary fat on insulin secretion in genetically diabetic Goto\u2013Kakizaki rats. Pancreas 25:393\u2013399","journal-title":"Pancreas"},{"key":"363_CR41","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.2337\/diacare.27.10.2450","volume":"27","author":"G Shetty","year":"2004","unstructured":"Shetty G, Economides P, Horton E, Mantzoros C, Veves A (2004) Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27:2450\u20132457","journal-title":"Diabetes Care"},{"key":"363_CR42","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2007.03.059","volume":"132","author":"S Shoelson","year":"2007","unstructured":"Shoelson S, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132:2169\u20132180","journal-title":"Gastroenterology"},{"key":"363_CR43","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.atherosclerosis.2005.05.009","volume":"184","author":"V Wong","year":"2006","unstructured":"Wong V, Stavar L, Szeto L, Uffelman K, Wang C, Fantus G, Lewis G (2006) Atorvastatin induces insulin sensitization in Zucker fatty rats. Atherosclerosis 184:348\u2013355","journal-title":"Atherosclerosis"},{"key":"363_CR44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nature01705","volume":"423","author":"T Yamauchi","year":"2003","unstructured":"Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al (2003) Cloning of adiponectin receptors that mediate antidiabetic effects. Nature 423:762\u2013769","journal-title":"Nature"},{"key":"363_CR45","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/07853890510037383","volume":"37","author":"H Yki-J\u00e4rvinen","year":"2005","unstructured":"Yki-J\u00e4rvinen H (2005) Fat in liver and insulin resistance. Ann Med 37:347\u2013356","journal-title":"Ann Med"},{"key":"363_CR46","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1111\/j.1530-0277.2006.00281.x","volume":"31","author":"M Yoneda","year":"2007","unstructured":"Yoneda M, Iwasaki T, Fujita K, Inamori M, Nozaki Y, Maeyama S et al (2007) Hypoadiponectinemia plays a crucial role in the development of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus independent of visceral adipose tissue. Alcohol Clin Exp Res 31:15S\u201321S","journal-title":"Alcohol Clin Exp Res"},{"key":"363_CR47","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2005.10.007","volume":"338","author":"H Zhou","year":"2005","unstructured":"Zhou H, Song X, Briggs M, Violand B, Salsgiver E, Luo Y (2005) Adiponectin represses gluconeogenesis independent of insulin in hepatocytes. Biochem Biophys Res Commun 338:793\u2013799","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-008-0363-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-008-0363-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-008-0363-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,19]],"date-time":"2021-09-19T04:54:27Z","timestamp":1632027267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-008-0363-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,21]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["363"],"URL":"https:\/\/doi.org\/10.1007\/s00210-008-0363-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,21]]}}}